Last updated: 2026-09-06 01:01:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Upstream Bio, Inc. (UPB) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $6.01, with a market capitalization of $354.92M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $5.77 to $33.68. This page covers its latest market performance, valuation, price trends and company information.
$354.92M | |
$6.00 | |
$33.68 | |
$5.14 | |
$6.08 | |
458.01K | |
-- | |
-- | |
$33.68 | |
$5.77 | |
-- | |
-- |
Upstream Bio, Inc. (UPB) last closed at $6.08 as of 2026-09-04 23:31:00, unchanged from the previous close of $6.08.
During the latest regular trading session, UPB traded between $5.14 and $33.68, with a volume of 458.01K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Upstream Bio, Inc. (UPB) moved from $6.64 to $6.01, representing a decline of 9.53% ($0.63).
The stock traded between $5.96 and $6.25 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 666.12 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 0.8%
UPB is currently trading at $6.01, placing it 0.8% of the way from its 52-week low of $5.77 to its 52-week high of $33.68. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. Verekitug has advanced into three separate world-wide, placebo-controlled, randomized Phase 2 clinical trials, two completed in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, and one ongoing in chronic obstructive pulmonary disease (COPD).
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 75 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Upstream Bio, Inc. (UPB) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.